Therefore, our study aims to analyze the value of serum NRG1 levels in prostate cancer patients before ADT, as well as NRG1 levels in biopsy tissues and NRG1 gene expression, for predicting CRPC progression within one year of ADT. This evidence concerns the gene NRG1 and prostate carcinoma.